{
    "abstract": "Vaccination against measles has reduced disease, although measles virus antibody (MVAb) levels are lower after vaccination than natural infection. Immunoglobulin (IG) preparations thus contain decreasing MVAb titers. US IG lot release requires a minimum titer of MVAb, yet equivalent information is not available for other geographies. Using a measles virus neutralization assay, IG fractionated from US or EU plasma is shown to contain similar levels of MVAb always above US regulatory requirements, supportive of equivalent protection against MV infection. Thus, the dosage for post-exposure prophylaxis in the EU could be aligned with the US FDA's treatment recommendations.",
    "author_highlights": [
        {
            "endOffset": 6820,
            "sentence": "Analysis of >1000 of intravenous immunoglobulins (IVIGs) from EU or US plasma",
            "startOffset": 6743
        },
        {
            "endOffset": 6899,
            "sentence": "IVIGs from US or EU plasma contain similar levels of measles virus antibodies.",
            "startOffset": 6821
        },
        {
            "endOffset": 6981,
            "sentence": "Measles post-exposure prophylaxis in EU could be aligned with US recommendations.",
            "startOffset": 6900
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Brith",
                    "initial": "B.",
                    "last": "Christenson"
                },
                {
                    "first": "Margareta",
                    "initial": "M.",
                    "last": "B\u00f6ttiger"
                }
            ],
            "doi": "10.1016/0264-410X(94)90049-3",
            "firstpage": "129",
            "issn": "0264410X",
            "lastpage": "133",
            "pmid": "8147093",
            "pub_year": 1994,
            "title": "Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus",
            "volume": "12"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Jens",
                    "initial": "J.",
                    "last": "Modrof"
                },
                {
                    "first": "Bj\u00f6rn",
                    "initial": "B.",
                    "last": "Tille"
                },
                {
                    "first": "Maria R.",
                    "initial": "M.R.",
                    "last": "Farcet"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "McVey"
                },
                {
                    "first": "Jessica A.",
                    "initial": "J.A.",
                    "last": "Schreiner"
                },
                {
                    "first": "Charles M.",
                    "initial": "C.M.",
                    "last": "Borders"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Gudino"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Fitzgerald"
                },
                {
                    "first": "Toby L.",
                    "initial": "T.L.",
                    "last": "Simon"
                },
                {
                    "first": "Thomas R.",
                    "initial": "T.R.",
                    "last": "Kreil"
                }
            ],
            "doi": "10.1093/infdis/jix428",
            "firstpage": "977",
            "issn": "00221899",
            "lastpage": "980",
            "pmid": "28968738",
            "pub_year": 2017,
            "title": "Measles Virus Neutralizing Antibodies in Intravenous Immunoglobulins: Is an Increase by Revaccination of Plasma Donors Possible?",
            "volume": "216"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Susette",
                    "initial": "S.",
                    "last": "Audet"
                },
                {
                    "first": "Maria Luisa",
                    "initial": "M.L.",
                    "last": "Virata-Theimer"
                },
                {
                    "first": "Judy A.",
                    "initial": "J.A.",
                    "last": "Beeler"
                },
                {
                    "first": "Dorothy E.",
                    "initial": "D.E.",
                    "last": "Scott"
                },
                {
                    "first": "Douglas J.",
                    "initial": "D.J.",
                    "last": "Frazier"
                },
                {
                    "first": "Malgorzata G.",
                    "initial": "M.G.",
                    "last": "Mikolajczyk"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Eller"
                },
                {
                    "first": "Feng Ming",
                    "initial": "F.M.",
                    "last": "Chen"
                },
                {
                    "first": "Mei Ying W.",
                    "initial": "M.Y.W.",
                    "last": "Yu"
                }
            ],
            "doi": "10.1086/506363",
            "firstpage": "781",
            "issn": "00221899",
            "lastpage": "789",
            "pmid": "16941344",
            "pub_year": 2006,
            "title": "Measles-virus-neutralizing antibodies in intravenous immunoglobulins",
            "volume": "194"
        },
        "b0020": null,
        "b0025": {
            "authors": [
                {
                    "first": "Meredith",
                    "initial": "M.",
                    "last": "Wadman"
                }
            ],
            "doi": "10.1126/science.363.6428.677",
            "firstpage": "677",
            "issn": "00368075",
            "lastpage": "678",
            "pmid": "30765543",
            "pub_year": 2019,
            "title": "Measles epidemic in Ukraine drove troubling European year",
            "volume": "363"
        },
        "b0030": null,
        "b0035": {
            "authors": [
                {
                    "first": "Albert",
                    "initial": "A.",
                    "last": "Farrugia"
                },
                {
                    "first": "Isabella",
                    "initial": "I.",
                    "last": "Quinti"
                }
            ],
            "doi": "10.1016/j.vaccine.2018.11.059",
            "firstpage": "3942",
            "issn": "0264410X",
            "lastpage": "3943",
            "pmid": "30497836",
            "pub_year": 2019,
            "title": "Herd immunity and primary immune deficiencies",
            "volume": "37"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Dorothea",
                    "initial": "D.",
                    "last": "Matysiak-Klose"
                },
                {
                    "first": "Sabine",
                    "initial": "S.",
                    "last": "Santibanez"
                },
                {
                    "first": "Christine",
                    "initial": "C.",
                    "last": "Schwerdtfeger"
                },
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "Koch"
                },
                {
                    "first": "Horst",
                    "initial": "H.",
                    "last": "von Bernuth"
                },
                {
                    "first": "Hartmut",
                    "initial": "H.",
                    "last": "Hengel"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Littmann"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Terhardt"
                },
                {
                    "first": "Sabine",
                    "initial": "S.",
                    "last": "Wicker"
                },
                {
                    "first": "Annette",
                    "initial": "A.",
                    "last": "Mankertz"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Heininger"
                }
            ],
            "doi": "10.1016/j.vaccine.2018.10.070",
            "firstpage": "7916",
            "issn": "0264410X",
            "lastpage": "7922",
            "pmid": "30478003",
            "pub_year": 2018,
            "title": "Post-exposure prophylaxis for measles with immunoglobulins revised recommendations of the standing committee on vaccination in Germany",
            "volume": "36"
        },
        "b0045": {
            "authors": [
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Poelsler"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Berting"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Kindermann"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Spruth"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "H\u00e4mmerle"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Teschner"
                },
                {
                    "first": "H. P.",
                    "initial": "H.P.",
                    "last": "Schwarz"
                },
                {
                    "first": "T. R.",
                    "initial": "T.R.",
                    "last": "Kreil"
                }
            ],
            "doi": "10.1111/j.1423-0410.2007.01016.x",
            "firstpage": "184",
            "issn": "00429007",
            "lastpage": "192",
            "pmid": "18167162",
            "pub_year": 2008,
            "title": "A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: Virus and prion reduction capacity",
            "volume": "94"
        },
        "b0050": null,
        "b0055": null,
        "b0060": {
            "authors": [
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Ritter"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Hamouda"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Offergeld"
                }
            ],
            "doi": "10.1007/s00103-012-1515-2",
            "firstpage": "914",
            "issn": "14369990",
            "lastpage": "922",
            "pmid": "22842884",
            "pub_year": 2012,
            "title": "Demography and donation frequencies of blood and plasma donor populations in Germany. Update 2010 and 5-year comparison",
            "volume": "55"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Alya",
                    "initial": "A.",
                    "last": "Dabbagh"
                },
                {
                    "first": "Rebecca L.",
                    "initial": "R.L.",
                    "last": "Laws"
                },
                {
                    "first": "Claudia",
                    "initial": "C.",
                    "last": "Steulet"
                },
                {
                    "first": "Laure",
                    "initial": "L.",
                    "last": "Dumolard"
                },
                {
                    "first": "Mick N.",
                    "initial": "M.N.",
                    "last": "Mulders"
                },
                {
                    "first": "Katrina",
                    "initial": "K.",
                    "last": "Kretsinger"
                },
                {
                    "first": "James P.",
                    "initial": "J.P.",
                    "last": "Alexander"
                },
                {
                    "first": "Paul A.",
                    "initial": "P.A.",
                    "last": "Rota"
                },
                {
                    "first": "James L.",
                    "initial": "J.L.",
                    "last": "Goodson"
                }
            ],
            "doi": "10.15585/MMWR.MM6747A6",
            "firstpage": "1323",
            "issn": "01492195",
            "lastpage": "1329",
            "pmid": "30496160",
            "pub_year": 2018,
            "title": "Progress toward regional measles elimination \u2014 worldwide, 2000\u20132017",
            "volume": "67"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Toby L.",
                    "initial": "T.L.",
                    "last": "Simon"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "FitzGerald"
                },
                {
                    "first": "Mirjam",
                    "initial": "M.",
                    "last": "K\u00fchne"
                },
                {
                    "first": "Connie",
                    "initial": "C.",
                    "last": "Farrar"
                },
                {
                    "first": "Jonathan",
                    "initial": "J.",
                    "last": "Knowles"
                },
                {
                    "first": "Keith",
                    "initial": "K.",
                    "last": "Bycholski"
                },
                {
                    "first": "Othmar",
                    "initial": "O.",
                    "last": "Zenker"
                }
            ],
            "doi": "10.1111/trf.15014",
            "firstpage": "3065",
            "issn": "00411132",
            "lastpage": "3071",
            "pmid": "30536437",
            "pub_year": 2018,
            "title": "Longitudinal changes in measles antibody titers in plasma donors and minimum antibody levels of immunoglobulin products for treatment of primary immunodeficiency",
            "volume": "58"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Vandeberg"
                },
                {
                    "first": "Maria Cristina",
                    "initial": "M.C.",
                    "last": "Cruz"
                },
                {
                    "first": "Rhonda",
                    "initial": "R.",
                    "last": "Griffin"
                }
            ],
            "doi": "10.1111/trf.15024",
            "firstpage": "3072",
            "issn": "00411132",
            "lastpage": "3077",
            "pmid": "30430616",
            "pub_year": 2018,
            "title": "Measles antibody trough levels after treatment with immunoglobulin products and predicted levels assuming lower measles antibody specifications",
            "volume": "58"
        },
        "b0080": null,
        "b0085": null
    },
    "body_text": [
        {
            "endOffset": 12704,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 12555,
                    "startOffset": 12551
                }
            },
            "secId": "s0020",
            "sentence": "As the IG lots tested here are produced by identical manufacturing process irrespective of the plasma origin [11] this difference in donor demography is reflected in higher MVAb titers in IG lots fractionated from recovered as compared to source plasma (Fig. 2).",
            "startOffset": 12442,
            "title": "Discussion"
        },
        {
            "endOffset": 8378,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 8322,
                    "startOffset": 8319
                },
                "b0015": {
                    "endOffset": 8377,
                    "startOffset": 8374
                }
            },
            "secId": "s0005",
            "sentence": "Wide use of the vaccine has resulted in a significant decrease in measles cases as well as in a progressive decline of MVAb titers in human plasma for fractionation [2] and thus in individual lots of immunoglobulin (IG) [3].",
            "startOffset": 8154,
            "title": "Introduction"
        },
        {
            "endOffset": 17240,
            "parents": [],
            "secId": "s0030",
            "sentence": "All authors reviewed the final version of the manuscript.",
            "startOffset": 17183,
            "title": "Author contributions"
        },
        {
            "endOffset": 17077,
            "parents": [],
            "secId": "s0030",
            "sentence": "M.R.F. and T.R.K. conceptualized the study.",
            "startOffset": 17034,
            "title": "Author contributions"
        },
        {
            "endOffset": 9266,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 9103,
                    "startOffset": 9100
                },
                "b0030": {
                    "endOffset": 9265,
                    "startOffset": 9262
                }
            },
            "secId": "s0005",
            "sentence": "Several US states and various European countries are subject to ongoing measles outbreaks [5], with notable recent increases e.g. in Austria, France, Poland, and Italy, and more than 10,000 cases and 33 deaths reported in Europe for the last 12 months [6].",
            "startOffset": 9010,
            "title": "Introduction"
        },
        {
            "endOffset": 15181,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 15180,
                    "startOffset": 15177
                }
            },
            "secId": "s0020",
            "sentence": "The data reported for 9 IG lots available on the German market 2015\u20132016 is fully consistent with this observation [8].",
            "startOffset": 15062,
            "title": "Discussion"
        },
        {
            "endOffset": 16736,
            "parents": [],
            "secId": "s0020",
            "sentence": "Further, data from the testing of >1000 lots of IG over the course of several years seems to indicate that the currently protective MVAb titers, as recently confirmed by US and EU regulatory bodies, seem to converge to a still protective steady-state, reflective of an only vaccinated donor population.",
            "startOffset": 16434,
            "title": "Discussion"
        },
        {
            "endOffset": 17136,
            "parents": [],
            "secId": "s0030",
            "sentence": "M.K., P.O.R., A.S. and R.I. curated and analyzed the data.",
            "startOffset": 17078,
            "title": "Author contributions"
        },
        {
            "endOffset": 10181,
            "parents": [],
            "secId": "s0010",
            "sentence": "Plasma was obtained either by plasmapheresis (source plasma), or from whole blood donations (recovered).",
            "startOffset": 10077,
            "title": "Methods"
        },
        {
            "endOffset": 15888,
            "parents": [],
            "secId": "s0020",
            "sentence": "With the MV vaccine in use for >50 years by now, and marginal circulation of MV in the geographies of plasma collection, a steady state reflective of an exclusively vaccinated plasma donor population should be expected at some point.",
            "startOffset": 15655,
            "title": "Discussion"
        },
        {
            "endOffset": 16265,
            "parents": [],
            "secId": "s0020",
            "sentence": "Collectively, this study demonstrates that the levels of MV neutralizing antibodies in IG preparations vary somewhat, depending on plasma type (recovered > source), as well as donor residence (EU > US).",
            "startOffset": 16063,
            "title": "Discussion"
        },
        {
            "endOffset": 11777,
            "parents": [],
            "secId": "s0020",
            "sentence": "Blood donors are generally of higher average age than source plasma donors.",
            "startOffset": 11702,
            "title": "Discussion"
        },
        {
            "endOffset": 10959,
            "parents": [],
            "secId": "s0015",
            "sentence": "Overall, EU plasma derived IG lots had higher MV neutralizing antibody titers (mean NT50[1:X] \u00b1 standard error of the mean (SEM); 1521 \u00b1 33) than US plasma derived IG lots (1373 \u00b1 13; p < 0.0001; Fig. 1).",
            "startOffset": 10755,
            "title": "Results"
        },
        {
            "endOffset": 13201,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 13085,
                    "startOffset": 13081
                }
            },
            "secId": "s0020",
            "sentence": "In addition, the WHO region Europe still reports an approximately 15-fold higher incidence of MV infections as compared to the WHO region Americas, i.e. 27 vs. 1.7 cases/million population [13], a consequence of inconsistent compliance with vaccination recommendations across the different European countries.",
            "startOffset": 12892,
            "title": "Discussion"
        },
        {
            "endOffset": 17014,
            "parents": [],
            "secId": "s0025",
            "sentence": "M.R.F., M.K., P.O.R. and T.R.K. are employees of Baxter AG, Vienna, Austria, now part of the Takeda group of companies, and Takeda stock owners.",
            "startOffset": 16870,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 9678,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 9623,
                    "startOffset": 9618
                },
                "b0040": {
                    "endOffset": 9623,
                    "startOffset": 9618
                }
            },
            "secId": "s0005",
            "sentence": "Given the significant clinical relevance and recently voiced concerns about regional differences between IG products [7,8], an in depth analysis of the topic was felt necessary.",
            "startOffset": 9501,
            "title": "Introduction"
        },
        {
            "endOffset": 17342,
            "parents": [],
            "secId": "s0035",
            "sentence": "This study was funded by Baxter AG, Vienna, Austria, now part of the Takeda group of companies.",
            "startOffset": 17247,
            "title": "Funding"
        },
        {
            "endOffset": 10076,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 9889,
                    "startOffset": 9886
                }
            },
            "secId": "s0010",
            "sentence": "MVAb titers were determined in 1739 IG lots (Gammgard Liquid / KIOVIG [Baxter Healthcare Corporation, Westlake Village, CA, USA]), fractionated between 2013 and 2018 by the same manufacturing process [9] from plasma collected in the US or in Austria, Germany and the Czech Republic (collectively designated EU), which constitute the leading European countries in terms of plasma collection.",
            "startOffset": 9686,
            "title": "Methods"
        },
        {
            "endOffset": 16869,
            "parents": [],
            "secId": "s0025",
            "sentence": "A.S. and R.I. are employees of Baxter AG, Vienna, Austria, now part of the Takeda group of companies.",
            "startOffset": 16768,
            "title": "Potential conflicts of interest"
        },
        {
            "endOffset": 13316,
            "parents": [],
            "secId": "s0020",
            "sentence": "Together, these factors could explain the higher MVAb titers seen in IG lots fractionated from EU plasma (Fig. 1).",
            "startOffset": 13202,
            "title": "Discussion"
        },
        {
            "endOffset": 15655,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 15654,
                    "startOffset": 15650
                }
            },
            "secId": "s0020",
            "sentence": "Of note, the current dosage recommendation for the UK is even lower [17].",
            "startOffset": 15582,
            "title": "Discussion"
        },
        {
            "endOffset": 12891,
            "parents": [],
            "secId": "s0020",
            "sentence": "As the measles vaccine was implemented around 10 years later in Europe than in the US, the proportion of previously MV infected donors is expected to be even greater in the EU countries.",
            "startOffset": 12705,
            "title": "Discussion"
        },
        {
            "endOffset": 11345,
            "parents": [],
            "secId": "s0015",
            "sentence": "This difference was evident in both geographies, when lots fractionated from US recovered (1966 \u00b1 31) and US source plasma (1222 \u00b1 10) as well as from EU recovered (2194 \u00b1 72) and EU source plasma (1366 \u00b1 28) were compared (Fig. 2).",
            "startOffset": 11113,
            "title": "Results"
        },
        {
            "endOffset": 11977,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 11888,
                    "startOffset": 11884
                },
                "b0055": {
                    "endOffset": 11976,
                    "startOffset": 11972
                }
            },
            "secId": "s0020",
            "sentence": "For example, in the USA, around 50% of all blood donations are contributed by donors over 45 years of age [10], while approximately 55% of the US source plasma donor pool is below the age of 35 [11].",
            "startOffset": 11778,
            "title": "Discussion"
        },
        {
            "endOffset": 11691,
            "parents": [],
            "secId": "s0015",
            "sentence": "For IG lots from US source plasma, which constitutes the quantitatively main starting material for IG production and thus the most robust source of data, a significant (p < 0.0001) decay of MVAb for the data analyzed was evident, while an equally significant (p < 0.0001) quadratic term confirmed that this decay is flattening with time (Fig. 3).",
            "startOffset": 11345,
            "title": "Results"
        },
        {
            "endOffset": 17182,
            "parents": [],
            "secId": "s0030",
            "sentence": "M.R.F., M.K. and T.R.K. wrote the manuscript.",
            "startOffset": 17137,
            "title": "Author contributions"
        },
        {
            "endOffset": 14622,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 14621,
                    "startOffset": 14618
                },
                "b0070": {
                    "endOffset": 14507,
                    "startOffset": 14500
                },
                "b0075": {
                    "endOffset": 14507,
                    "startOffset": 14500
                }
            },
            "secId": "s0020",
            "sentence": "Two clinical studies have recently investigated the MVAb trough (intravenous IG) or steady state (subcutaneous IG) levels in treated PID [14,15], and found these above protective levels, even when extrapolated to the now lowered FDA release specification [4].",
            "startOffset": 14363,
            "title": "Discussion"
        },
        {
            "endOffset": 16063,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 15987,
                    "startOffset": 15984
                }
            },
            "secId": "s0020",
            "sentence": "Indeed, such a steady-state was noted in a recent study of MV neutralizing titers in US plasma [2] and was confirmed in the present study for MVAb titers in IG lots (Fig. 3).",
            "startOffset": 15889,
            "title": "Discussion"
        },
        {
            "endOffset": 10419,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 10418,
                    "startOffset": 10415
                }
            },
            "secId": "s0010",
            "sentence": "Titers were determined as neutralization titer NT50 [1:X], i.e. the reciprocal dilution resulting in 50% MV neutralization, by a fully validated neutralization assay on Vero cells (ATCC CCL-81) in duplicate, essentially as described [2].",
            "startOffset": 10182,
            "title": "Methods"
        },
        {
            "endOffset": 13637,
            "parents": [],
            "secId": "s0020",
            "sentence": "However, while different with high statistical significance, the mean values of MVAb titers of the four subgroups of IG determined by plasma collection modality (source vs. recovered), as well as collection geography (US vs. EU), were within a factor of only two, i.e. the IG dilution increments used for the MVAb assay.",
            "startOffset": 13317,
            "title": "Discussion"
        },
        {
            "endOffset": 13982,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 13981,
                    "startOffset": 13978
                }
            },
            "secId": "s0020",
            "sentence": "The serum level of MVAb that corresponds with clinical protection has been reported as >120 mIU/mL [4].",
            "startOffset": 13879,
            "title": "Discussion"
        },
        {
            "endOffset": 9500,
            "parents": [],
            "secId": "s0005",
            "sentence": "This highlights the importance of protective MVAb titers in IG, but other than for lots released to the US market, determination of MVAb titers in IG preparations is not required, and this information is thus not generally available.",
            "startOffset": 9267,
            "title": "Introduction"
        },
        {
            "endOffset": 15581,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 15580,
                    "startOffset": 15576
                }
            },
            "secId": "s0020",
            "sentence": "The German Standing Committee on Vaccination (STIKO) also recommends 400 mg/kg BW in at-risk populations; a lower dose (200 mg/kg BW), i.e without the safety margin, is recommended by the French National Competent Authority ANSM [16].",
            "startOffset": 15347,
            "title": "Discussion"
        },
        {
            "endOffset": 8153,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 8152,
                    "startOffset": 8149
                }
            },
            "secId": "s0005",
            "sentence": "Vaccination-induced measles virus antibody (MVAb) titers are lower than after natural infection [1].",
            "startOffset": 8053,
            "title": "Introduction"
        },
        {
            "endOffset": 16433,
            "parents": [],
            "secId": "s0020",
            "sentence": "While statistically significant, the relatively minor variation as compared to assay precision supports similar protective properties for all IG preparations analyzed.",
            "startOffset": 16266,
            "title": "Discussion"
        },
        {
            "endOffset": 8828,
            "parents": [],
            "secId": "s0005",
            "sentence": "In the same announcement, amended treatment recommendations for the passive protection of people with immune deficiencies (PID), both prophylactically as well as after potential exposure, were defined, to ensure adequate protection.",
            "startOffset": 8596,
            "title": "Introduction"
        },
        {
            "endOffset": 12205,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 12204,
                    "startOffset": 12200
                }
            },
            "secId": "s0020",
            "sentence": "In Germany, the country that contributes the highest volume of plasma for fractionation in Europe, 19% of repeat whole blood donors were 55+ years of age, while only 4.7% of plasmapheresis donors fell into this age cohort [12].",
            "startOffset": 11978,
            "title": "Discussion"
        },
        {
            "endOffset": 10747,
            "parents": [],
            "secId": "s0010",
            "sentence": "Between-group comparisons were conducted with GraphPad Prism using an unpaired t-test, while longitudinal statistical analysis was performed with MiniTab v17 software using a second order polynomial model.",
            "startOffset": 10542,
            "title": "Methods"
        },
        {
            "endOffset": 10541,
            "parents": [],
            "secId": "s0010",
            "sentence": "Data was processed using R software (www.rstudio.com) and visualization was performed with GraphPad Prism v7.03 software.",
            "startOffset": 10420,
            "title": "Methods"
        },
        {
            "endOffset": 12441,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 12440,
                    "startOffset": 12437
                }
            },
            "secId": "s0020",
            "sentence": "It can therefore be expected that a larger proportion of blood donors were born before introduction of the measles vaccine in 1963, who are thus more likely to have experienced MV infection, which results in higher antibody titers [1].",
            "startOffset": 12206,
            "title": "Discussion"
        },
        {
            "endOffset": 13878,
            "parents": [],
            "secId": "s0020",
            "sentence": "Thus, whether plasma is collected in the US or EU, and whether the starting material is either source or recovered plasma, IG derived thereof may be considered as functionally equivalent with respect to protection against measles infection.",
            "startOffset": 13638,
            "title": "Discussion"
        },
        {
            "endOffset": 11112,
            "parents": [],
            "secId": "s0015",
            "sentence": "MVAb titers for IG lots fractionated from recovered plasma (2000 \u00b1 29) were significantly higher (p < 0.0001) than those from source plasma (1245 \u00b1 10).",
            "startOffset": 10960,
            "title": "Results"
        },
        {
            "endOffset": 8595,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 8594,
                    "startOffset": 8591
                }
            },
            "secId": "s0005",
            "sentence": "The minimum MVAb specification for IG lot release in the US, as defined by Food and Drug Administration (FDA), has been increasingly difficult to meet, and in November 2018 was lowered to avoid product shortages [4].",
            "startOffset": 8379,
            "title": "Introduction"
        },
        {
            "endOffset": 14363,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 14362,
                    "startOffset": 14359
                }
            },
            "secId": "s0020",
            "sentence": "Also, while testing for a minimum threshold of MVAb is only required for release of IG to the US, all EU plasma lots fulfilled the lot release criterion as per FDA regulation even before the recent limit adjustment from previously 0.48 \u00d7 CBER Standard lot 176 to currently 0.36 \u00d7 CBER Standard lot 176 (estimated titer of CBER Standard lot 176, a 16.5% solution, is 42 IU/mL) [4].",
            "startOffset": 13983,
            "title": "Discussion"
        },
        {
            "endOffset": 14808,
            "parents": [],
            "secId": "s0020",
            "sentence": "Beyond PID treatment, IG is also indicated for post-exposure prophylaxis in individuals not eligible for vaccination, such as infants and unvaccinated pregnant women exposed to measles.",
            "startOffset": 14623,
            "title": "Discussion"
        },
        {
            "endOffset": 15346,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 15306,
                    "startOffset": 15303
                }
            },
            "secId": "s0020",
            "sentence": "Post-exposure prophylaxis in the EU should thus be aligned with US recommendations of 400 mg/kg body weight (BW) for PID [4], i.e. including a 2-fold safety margin.",
            "startOffset": 15182,
            "title": "Discussion"
        },
        {
            "endOffset": 15061,
            "parents": [],
            "secId": "s0020",
            "sentence": "The current study, which presents the test results for >1000 IG lots, reliably demonstrates that IG lots available in the EU are functionally similar, if not somewhat superior, to IG lots available in the US, with respect to MV neutralizing antibodies.",
            "startOffset": 14809,
            "title": "Discussion"
        },
        {
            "endOffset": 9009,
            "parents": [],
            "secId": "s0005",
            "sentence": "Beyond PID, however, passive protection also remains the only available intervention to safeguard at-risk populations not eligible for vaccination, i.e. pregnant women or newborns.",
            "startOffset": 8829,
            "title": "Introduction"
        }
    ],
    "docId": "S0264410X19304736",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "maria.farcet@takeda.com",
                "first": "Maria R.",
                "initial": "M.R.",
                "last": "Farcet"
            },
            {
                "email": "michael.karbiener@takeda.com",
                "first": "Michael",
                "initial": "M.",
                "last": "Karbiener"
            },
            {
                "email": "philip.rabel@takeda.com",
                "first": "Philip O.",
                "initial": "P.O.",
                "last": "Rabel"
            },
            {
                "email": "andreas.schirmer@takeda.com",
                "first": "Andreas",
                "initial": "A.",
                "last": "Schirmer"
            },
            {
                "email": "reinhard.ilk@takeda.com",
                "first": "Reinhard",
                "initial": "R.",
                "last": "Ilk"
            },
            {
                "email": "thomas.kreil@takeda.com",
                "first": "Thomas R.",
                "initial": "T.R.",
                "last": "Kreil"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.04.022",
        "firstpage": "3151",
        "issn": "0264410X",
        "keywords": [
            "IGIV",
            "Immunoglobulin, intravenous",
            "Immunoglobulin, subcutaneous",
            "Measles vaccination",
            "Neutralization assays",
            "Post-exposure prophylaxis"
        ],
        "lastpage": "3153",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Measles virus neutralizing antibodies in immunoglobulin lots produced from plasma collected in Europe or the United States"
    }
}